Congenital Trypanosoma cruzi infection in neonates and infants from two regions of Chile where Chagas' disease is endemic.

Chagas’ disease, or American trypanosomiasis, whose etiological agent is the protozoan parasite Trypanosoma cruzi, is an important public health concern in Latin America. At least 8 million people acquired the infection via the arthropod vector or another mechanism of transmission, such as blood transfusion or vertical transmission from mother to child (9). In Chile (11), the parasitose is endemic and enzootic in the northern and central biogeographical regions (18°30 S to 34°36 S). Three species of Reduviidae insect are transmitters of Chagas’ disease to mammals, including humans, in Chile: Triatoma infestans, Triatoma spinolai, and Mepraia gajardoi (3, 13). Modes of transmission of Chagas’ disease other than infections through insect vectors have been documented to occur in Chile, including accidental laboratory infections, infections caused by blood transfusion, and transplacental infections. Infections by the oral route in humans have not been described to occur in Chile (12). Epidemiological studies conducted in previous decades, mainly with blood banks in areas where Chagas’ disease is endemic, with hospital maternity wards, and with specific age groups, especially children, as well as an intensive campaign of T. infestans disinfestations promoted by the Chilean health authority, have led to accurate knowledge of the epidemiological aspects of Chagas’ disease and the control of transmission by those insect vectors and in blood banks in areas of the country where Chagas’ disease is endemic and enzootic (4, 8, 11). In 1999, this led to the declaration of the interruption of transmission of Chagas’ disease via the T. infestans vector in Chile (1). However, the emergence of new cases of T. cruzi infections in Chile both in blood banks and via transplacental infection maintains the importance of systematic studies on the epidemiological and epizootic aspects of this parasitic disease in Chile (4). Congenital Chagas’ disease is considered the principal mode of T. cruzi infection in geographical areas where transmissions by insect vectors and blood transfusion are controlled (15). PCR used in laboratory diagnosis of Chagas’ disease is considered a sensitive and specific test and additionally a useful probe for evaluating the efficacy of treatment of infected patients (14, 15). Since there have been few studies of Chagas’ disease in recent years in Chile, in the present research we describe the use of kinetoplast KNA (kDNA) PCR to detect T. cruzi infections in neonates and infants born from mothers with Chagas’ disease in two regions of Chile where Chagas’ disease is endemic. The purpose of this research was to determine the frequency of congenital infections in children delivered from chagasic mothers by using PCR for kDNA as a laboratory diagnostic tool. During the years 2007 and 2008 at the Reference Laboratory of Parasitology of the Institute of Public Health of Chile (ISP), blood samples from 179 children less than 2 years of age from regions IV and V of Chile were received. In those regions, samples were collected in maternity wards of hospitals in the cities of Ovalle (region IV) and La Serena (region V) and in the hospitals of Los Andes, San Camilo, and Gustavo Fricke, located in region V. The blood samples were collected systematically as part of a chagasic infection screening program launched by the Health Ministry of Chile (MINSAL) in these geopolitical regions of the country. Samples were taken under the guidance of the ethics committee for scientific research of the ISP-MINSAL. The ages of the children ranged from 1 day to 2 years 8 months. Eighty-two (45.8%) children were less than 3 days of age, 15.1% (27/179) were between 4 and 15 days old, 30.2% (54/179) were more than 15 days and less 1 year old, and 8.9% (16/179) were 1 year to 2 years 8 months old; 98 were female (54.7%), and 81 were male (45.3%). Samples were taken from peripheral blood and stored until shipment to the laboratory where they were processed. With each sample, we performed an indirect immunofluorescence assay (IF) and an enzyme-linked immunosorbent assay (ELISA) for detecting serum-specific antibodies to T. cruzi (2, 14). PCR was performed as described by Wincker et al. (16), with the following modifications. DNA was extracted with a commercial kit (FavorPrep blood genomic DNA extraction minikit) in accordance with the instructions of the supplier. With this extracted DNA, PCR was performed using 2.5 l of each sample. We used primer 121 (5 TAA TGT AAA ACG GGG GAG ATG CAT GA 3 ) (10 mol/liter) and primer 122 (5 GGT TCG ATT GGG GTT GGT GTA ATA TA 3 ) (10 mol/liter) to amplify a region of the kinetoplast DNA of T. cruzi. As a control for the integrity of the extracted DNA and inhibition of PCR, we amplified a DNA segment of the human -globin gene by use of the following primers: b_glo1 (5 CCT CCT TTG AAG TTC TCC AA 3 ) and b_glo 2 (5 CCT CTT CAC TCA TGG CTT AG 3 ). In each run, a negative (no-DNA) sample and positive controls (T. cruzi DNA, Tulahuen strain) were included. Amplification products were visualized by agarose gel electrophoresis in 2% ethidium bromide, using a running time of 55 min at 107 mV. Samples were considered positive when a 330-bp product was amplified by primers 121/122. Primers for b_glo1/b_glo2 amplified a 239-bp product (10). In region IV of Chile, most of the samples studied were from the Ovalle hospital. In region V, most samples were derived from the G. Fricke and Los Andes hospitals. All serum samples were IF and ELISA positive ( 1:20 serum dilution). A positive PCR result, detecting kDNA of T. cruzi in blood samples of the 179 neonates and infants, was found in 15 cases (8.4%). Of the 15 PCR-positive samples, 9 were from region V. The frequencies of T. cruzi infections observed in the two biogeographical regions were not significant by a chi-square test (Table 1). We also observed no significant difference in the percentages of transplacental T. cruzi infection by sex: females, 9.2% (9/98), and males, 7.4% (6/81) ( 2 0.18; P 0.67). Figure 1 shows the results for the 15 positive PCR results, with a 330-bp band of kDNA of T. cruzi. The -globin control amplification showed a band of 239 bp. The 8.4% rate of positive PCR results for kDNA of T. cruzi